Avalyn Pharma Inc.
No annual data found.
Avalyn Pharma raised $345.0 million in upsized IPO and reported cash position of $123.1 million as of Q1 2026, with clinical programs on track including MIST Phase 2b trial enrollment for AP01 expected mid-2026
“By delivering inhaled therapies directly to the lungs through nebulization, our programs are designed to address the urgent gap in treatments for these deadly diseases.”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-05-05 | Novo Holdings A/S | 10% Owner | Purchase | 555.6K | $18.00 | $10.00M | 3.88M | View | |
| 2026-05-01 | 2026-05-01 | Carroll Jill | Director | Purchase | 277.8K | $18.00 | $5.00M | 2.19M | View | |
| 2026-05-01 | 2026-05-01 | SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Purchase | 277.8K | $18.00 | $5.00M | 1.12M | View |
Informational purposes only, not investment advice.